Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nedosiran in Pediatric Patients With Primary Hyperoxaluria
NCT05001269Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2022
- Primary completion
- Feb 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of nedosiran in Primary hyperoxaluria (PH), sponsored by Novo Nordisk. Primary endpoints: Percent Change From Baseline to Month 6 in Spot Urinary Oxalate-to-creatinine Ratio and Absolute Change From Baseline to Month 6 in Spot Urinary Oxalate-to-creatinine Ratio. Started Feb 2022; status: completed.
02
Drugs
nedosiran
03
Conditions
Primary hyperoxaluria (PH)
Beyond the preview
Go deeper on NCT05001269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001269.